Better Health for All

Editas Medicine is focused on developing transformative genomic medicines using CRISPR technology, directly contributing to better health outcomes

. Clinical trial data for EDIT-301 (reni-cel) shows promising results in patients with sickle cell disease, with significant improvements in hemoglobin levels and a well-tolerated safety profile , . 27 out of 28 patients in the RUBY trial were free of vaso-occlusive events (VOE) . The company is actively investing in health innovation, as evidenced by the ongoing development of reni-cel . However, the high cost of gene therapies raises concerns about price accessibility, potentially limiting access for vulnerable populations . The company plans to enroll 40 patients in a Phase 1/2 sickle cell study . Given the potential for significant health benefits and ongoing clinical development, a score of +40 is warranted.

Fair Money & Economic Opportunity

Editas Medicine, Inc. is a clinical-stage genome editing company focused on developing genomic medicines.

The provided articles consistently state that the company's core business is gene editing research and development, not financial services. Therefore, it does not offer lending, deposit services, or other financial products to consumers. As such, all Key Performance Indicators related to Fair Money & Economic Opportunity are not applicable to Editas Medicine's operations.

Fair Pay & Worker Respect

The company's CEO-to-median employee pay ratio was 13:1 in 2020.

Employee reviews indicate that 61% of employees would recommend working at the company and 61% approve of the CEO. In January 2023, approximately 60 employees were impacted by layoffs out of a total of 264 employees.

Honest & Fair Business

Editas Medicine has a comprehensive Code of Business Conduct & Ethics, last updated in September 2024, which includes a whistle-blower policy.

This policy allows employees to confidentially and anonymously report concerns about accounting or auditing matters to the Audit Committee via mail, email, website, or a toll-free telephone number. The company explicitly states it will not discipline, discriminate against, or retaliate against any employee who reports a complaint or concern, unless the report was made with knowledge that it was false. A record of all complaints and concerns received is provided to the Audit Committee each fiscal quarter. The company has not had any financial restatements in the past five years, as indicated by unchecked boxes in its 10-K filings for error corrections and restatements requiring recovery analysis. The company also has an anti-corruption policy that prohibits the use of company funds or assets for gifts, gratuities, or other favors to government officials, except when compliant with applicable law and insignificant in amount. It strictly prohibits bribes and kickbacks globally, referencing the Foreign Corrupt Practices Act.

Kind to Animals

Editas Medicine conducts preclinical trials on animals, including in vivo studies in non-human primates and humanized mice, as a required step in developing biological products.

These animal studies evaluate potential efficacy and toxicity and are generally referred to as IND-enabling studies. The company must report findings from animal testing that suggest significant risk in humans to the FDA and comply with FDA's Good Laboratory Practice regulations. There is no evidence of a policy to prohibit discretionary testing or require high-level sign-off for exceptions, indicating that legal mandates override alternatives.

No War, No Weapons

Editas Medicine, Inc. is a clinical-stage genome editing company. The provided articles do not contain specific, concrete data points for any of the KPIs related to the 'No War, No Weapons' value. While one article mentions the company's total lobbying expenditures for 2020 were $100,000 in the Pharmaceuticals/Health Products industry, there is no information on the specific nature or purpose of this lobbying, particularly whether it supported or opposed arms control legislation.

Therefore, no KPIs can be scored based on the available evidence.

Planet-Friendly Business

Editas Medicine reported annual carbon emissions of 47.6 metric tons CO2 equivalent.

Given the company's primary activities as a clinical-stage genome editing company, this level of emissions is considered not material. The company generates 3.2 metric tons of laboratory waste annually. Waste segregation protocols indicate 62% of biological waste is recycled or neutralized, 38% of chemical waste undergoes specialized disposal, and 100% of electronic waste is sent for certified e-waste recycling. This suggests a waste diversion rate between 10-20%. The company has achieved full compliance with ISO 14001:2015 and 100% adherence to EPA Biotechnology Regulations, with no reported environmental compliance violations.